The purpose of this study was to investigate the differences in pathologic response and survival outcomes between dose-dense and standard-interval chemotherapy in patients with HER2-positive breast cancer who receive neoadjuvant chemotherapy (NAC), including an anthracycline-based regimen followed by paclitaxel and trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.